Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ting CY and Shahdadpuri R | Fuchs syndrome: a case of fever, mucositis and conjunctivitis. | 2018 | BMJ Case Rep | pmid:29378740 |
| Afghani T et al. | Preventing Long-Term Ocular Complications of Trachoma With Topical Azithromycin: A 3-Year Follow-up Study. | 2017 Jan-Feb | Asia Pac J Ophthalmol (Phila) | pmid:28161923 |
| O'Brien KS et al. | Mass Azithromycin and Malaria Parasitemia in Niger: Results from a Community-Randomized Trial. | 2017 | Am. J. Trop. Med. Hyg. | pmid:28722569 |
| Stoney RJ et al. | Travelers' Diarrhea and Other Gastrointestinal Symptoms Among Boston-Area International Travelers. | 2017 | Am. J. Trop. Med. Hyg. | pmid:28719282 |
| Harper LM et al. | Economic Evaluation of Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. | 2017 | Obstet Gynecol | pmid:28697108 |
| Fan LC et al. | Macrolides protect against infection via inhibition of inflammasomes. | 2017 | Am. J. Physiol. Lung Cell Mol. Physiol. | pmid:28684545 |
| Bystrzycka W et al. | Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) Release. | 2017 | Int J Mol Sci | pmid:29292737 |
| Ullah S et al. | Creatinine-based non-phospholipid vesicular carrier for improved oral bioavailability of Azithromycin. | 2017 | Drug Dev Ind Pharm | pmid:28157445 |
| Mohammed H et al. | First line dual therapy for gonorrhoea to limit the spread of antimicrobial resistance. | 2017 | BMJ | pmid:28153820 |
| Oluwalana C et al. | Azithromycin in Labor Lowers Clinical Infections in Mothers and Newborns: A Double-Blind Trial. | 2017 | Pediatrics | pmid:28130432 |
| Gibson PG et al. | Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. | 2017 | Lancet | pmid:28687413 |
| Molefe NI et al. | Oral administration of azithromycin ameliorates trypanosomosis in Trypanosoma congolense-infected mice. | 2017 | Parasitol. Res. | pmid:28674747 |
| Haque F et al. | Evaluation of a Smartphone Decision-Support Tool for Diarrheal Disease Management in a Resource-Limited Setting. | 2017 | PLoS Negl Trop Dis | pmid:28103233 |
| Bulman ZP et al. | Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. | 2017 | Antimicrob. Agents Chemother. | pmid:28096154 |
| Björnelius E et al. | macrolide resistance in Stockholm, Sweden. | 2017 | Sex Transm Infect | pmid:27502694 |
| O'Rourke VJ | Azithromycin as an adjunct to non-surgical periodontal therapy: a systematic review. | 2017 | Aust Dent J | pmid:27492140 |
| Xue Y et al. | An in vitro model of azithromycin-induced persistent Chlamydia trachomatis infection. | 2017 | FEMS Microbiol. Lett. | pmid:28854672 |
| Murray K et al. | Increasing Antibiotic Resistance in Shigella spp. from Infected New York City Residents, New York, USA. | 2017 | Emerging Infect. Dis. | pmid:28098543 |
| Nichols DP et al. | Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. | 2017 | J. Cyst. Fibros. | pmid:28025037 |
| Marks M et al. | Mathematical Modeling of Programmatic Requirements for Yaws Eradication. | 2017 | Emerging Infect. Dis. | pmid:27983500 |